Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 17, 2018
Pharmacy Choice - News - Generic Drugs - July 17, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 69     Next >>     Go To Page:

7/16/18 - Aucta Receives its First Product Approval and Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone?
Aucta Pharmaceuticals, Inc. announced today that it has begun shipping Vigabatrin for Oral Solution, USP, 500 mg, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Aucta's commercial partner Upsher-Smith Laboratories, LLC will launch vigabatrin for oral solution under the brand name Viga
7/16/18 - Biosimilar Market by 2025: Top Players Like Pfizer, Roche, Eli Lilly, Bayer, Amgen, Sanofi-Aventis, Merck: The Worldwide Biosimilar market is the more professional in-depth of this market is providers the status and forecast, categorizes the global B
New York, NY 07/16/2018 The Study Paper on Top key vendors in Biosimilar Market include are Pfizer, Roche, Eli Lilly, Bayer, Amgen, Sanofi-Aventis, Johnson& Johnson, Novo Nordisk, Merck. Download FREE Sample Brochure@ https://www.marketexpertz.com/sample-enquiry-form/13850. Apart from this, the valuable document weighs upon the performance of
7/16/18 - Chronic Heart Failure Market: Important Changes in Market Dynamics
Albany, NY 07/16/2018 The Chronic Heart Failure Market is an advanced market, wherein branded drugs are increasingly being taken over by generic drugs. The CHF market presently has scanty pipeline of brand-name drugs and is heavily laden with generic drugs. Chronic heart failure is a serious condition and is progressive.
7/16/18 - Comprehensive study explore how - Biosimilar Testing and Development Services Market will grow in Forecast Year 2025
Latest research study from HTF MI with title Global Biosimilar Testing and Development Services by Manufacturers, Regions, Type and Application, Forecast to 2023. The Research report presents a complete assessment of the market and contains Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported
7/16/18 - Comprehensive study explore how Biosimilar Testing and Development Services Market will grow in Forecast Year 2025
"Global Biosimilar Testing and Development Services Market Size, Status and Forecast 2025" Latest research study from HTF MI with title Global Biosimilar Testing and Development Services by Manufacturers, Regions, Type and Application, Forecast to 2023. The Research report presents a complete assessment of the market and contains Future trend, Curr
7/16/18 - Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy's Laboratories from Launching its Generic Suboxone Product
Aquestive Therapeutics announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC and its U.S. subsidiary, Indivior Inc., a preliminary injunction against Dr. Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing...
7/16/18 - Endo Begins Shipment of Authorized Generic Version of Colcrys colchicine, USP in the United States
By a News Reporter-Staff News Editor at Pharma Business Week Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys 0.6 mg tablets. Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and dist
7/16/18 - FDA joins 22 countries` recall of common heart drug [Arab Finance (Egypt)]
A common drug used to control blood pressure and help prevent heart failure was announced by the US Food and Drug Administration on Friday, a week after 22 other countries recalled it because the drug contains a chemical that poses a potential cancer risk. Valsartan is off patent and is used as a component of other generic medicines, but not all me
7/16/18 - FDA Withdraws its Pivotal Biosimilar Products Testing Guideline After Sarfaraz Niazi, founder of Pharmaceutical Scientist, Files the First Citizen...
FDA Withdraws its Pivotal Biosimilar Products Testing Guideline After Sarfaraz Niazi, founder of Pharmaceutical Scientist, Files the First Citizen Petition Challenging its Clinical Relevance. By a News Reporter-Staff News Editor at Pharma Business Week In an unprecedented move on 21 June 2018, the FDA withdrew the draft guidance, "Statistical App
7/16/18 - Global Antimicrobial Resistance Diagnostics Market 2018-2023: Multiple Diagnostic Technologies Create New Global Race
1.2. 1 Revenue Market Size 1.3 Methods and Sources 1.4 U.S. Antibiotic Markets- Perspective 1.4. 1 U.S. Outpatient Use of Antibiotics 1.4. 2 U.S. Pharmaceutical Spending 2. Overview of a Dynamic Market 2.1 Market Players- Roles& Impacts 2.1. 1 Drug manufacturers- Larger/pharmaceutical 2.1. 2 Drug manufacturers- Generic 2.1. 3 Contract Research and
7/16/18 - Intellipharmaceutics Announces Second Quarter 2018 Results
TORONTO, ON/ ACCESSWIRE/ July 16, 2018/ Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2018.
7/16/18 - Lupin receives FDA approval for generic Nitrofurantoin Capsules USP, 50 mg and 100 mg
Mumbai- Pharma major Lupin announced that it has received final approval for its Nitrofurantoin Capsules USP, 50 mg and 100 mg from the United States Food and Drug Administration to market a generic version of Alvogen Malta Operations Ltd.' s Macrodantin Capsules, 50 mg and 100 mg. Lupin's Nitrofurantoin Capsules USP, 50 mg and 100 mg is the generi
7/16/18 - MLA pushes for generic medicine store at GMCH [Sport360]
Acting on the Centres push for generic drugs, MLA Atul Save has made a pitch for setting up a dedicated generic medicine store Jan Aushadhi Kendra at the Government Medical College and Hospital in the state assembly. Though this problem has plagued the government hospital for far too long, the state governments directive of 2017 to procure medicine
7/16/18 - Nicergoline Market in China 2018-2022: Kunshan Rotam Reddy Pharmaceutical Leads the Competition - ResearchAndMarkets.com
By a News Reporter-Staff News Editor at Pharma Business Week The "Investigation Report on Nicergoline in China, 2018-2022" report has been added to ResearchAndMarkets.com' s offering. According to analysis, due to the expired patent of nicergoline in China, the market has been dominated by generic drugs. Its market share exceeded 60% in 2017, and
7/16/18 - Report Summarizes Biosimilars Study Findings from University of Pisa (Transitioning from first- to second-generation biosimilars: An appraisal of...
Report Summarizes Biosimilars Study Findings from University of Pisa. According to news reporting from Pisa, Italy, by NewsRx journalists, research stated, "Second-generation biosimilars differ in several respects as compared to first-generation ones. The news correspondents obtained a quote from the research from the University of Pisa, "Based on
7/16/18 - Slayback Pharma Appoints Joan Janulis as Head of Global Regulatory Affairs
Ms Janulis is a highly accomplished Regulatory Affairs leader with extensive knowledge of the US FDA regulations and best practices and a stellar track record on both the generic pharma as well as the 505 b2 side. Ms. Janulis has held various executive positions at Vensun, Faulding/Purepac Pharmaceutical, Ivax Pharmaceuticals, and Able Laboratories
7/16/18 - Upsher-Smith Launches Vigabatrin For Oral Solution Under The Brand Name Vigadrone?
The Vigabatrin powder market had U.S. sales of approximately $333 million for the 12 months ending December 31, 2017 according to IQVIA. Upsher-Smith partnered with Aucta Pharmaceuticals, LLC for product development and manufacturing. Vigadrone? is supported by Upsher-Smith's Access Pathways Program, which is designed to reduce the barriers...
7/16/18 - Xbrane and STADA enter into a co-development agreement for Xlucane
Xbrane Biopharma AB and STADA Arzneimittel AG have entered into a co-development agreement for Xlucane, a Lucentis biosimilar. The co-development agreement covers Europe, the US and a variety of MENA and APAC markets. Martin Amark, CEO of Xbrane says:' We are very excited to enter into this co-development partnership with STADA.
7/15/18 - SMi's Biosimilars & Biobetters Exclusive Interview with Expert Speaker Dr Michel Mikhail Released
SMi Reports: An exclusive interview with Dr Michel Mikhail, an independent consultant and chairman of this year's Biosimilars & Biobetters conference, is now available to download on the event website.
7/14/18 - A FINE LINE TO TREAT PAIN AS EPIDEMIC WORSENS
Opioids have had horrible effects on St. Louis County and Minnesota. Jon Marcaccini, an area pharmacist who has owned and operated Jon's Drug in Eveleth since 1983, explained the how the drugs work on the human body. Heroin is used as a legal pain medication in many countries, including the United Kingdom, under the generic name Diamorphine.
7/14/18 - Apotex Focuses on High Growth Markets with Sale of European Generics Business
-Apotex, Canada's largest generic pharmaceutical company, has signed an agreement to sell its commercial operations and certain supporting infrastructure for its generics business in five European countries to Aurobindo Pharma Limited. "This is a positive move for our organization and enables us to further accelerate our efforts to drive additiona
7/14/18 - CMA opens six new investigations into anticompetitive drug pricing [Tehran Times (Iran)]
The Pharmaceutical Journal has learned that the Competitions and Market Authority opened six new investigations in October 2017, at the height of the crisis in the generics market that hit community pharmacy hard. The CMA refused to confirm whether any of the latest investigations were linked to generic manufacturers or wholesalers, but the news co
7/14/18 - Suresh Prabhu asks pharma companies to invest in R&D [Arab Finance (Egypt)]
Commerce and Industry Minister Suresh Prabhu today asked pharmaceutical companies to invest in research and development to bolster the growth of the sector. India is now recognised as a key player globally in the generic medicine industry. It is not just in India, but all over the world, there is a clamour for controlling drug prices, Prabhu said a
7/14/18 - Tender Enquiry No 05 for Supply of Generic Drugs for a Period of Two Years from the Date of Conclusion of Rate Contract
Company: DIRECTORATE GENERAL HEALTH SERVICES, MHFW. Ministry/Department Ministry of Health and Family Welfare Govt Medical Store Depot C-4 Qutub Institutional Area New Delhi-110016 Attn: Dr Vinay Kumar Mishra Cmo in Charge. Description: Tenders are invited for Tender Enquiry No 05 for Supply of Generic Drugs for a Period of Two Years from the Date
7/14/18 - Tender Enquiry No 06 for Supply of Generic Drugs for a Period of Two Years from the Date of Conclusion of Rate Contract
Company: DIRECTORATE GENERAL HEALTH SERVICES, MHFW. Ministry/Department Ministry of Health and Family Welfare Govt Medical Store Depot C-4 Qutub Institutional Area New Delhi-110016 Attn: Dr Vinay Kumar Mishra Cmo. Description: Tenders are invited for Tender Enquiry No 06 for Supply of Generic Drugs for a Period of Two Years from the Date of Conclus
Articles(s): 1 - 25 of 69     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415